Japan Rebound For Amgen With Daiichi Biosimilars Deal
Executive Summary
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
You may also be interested in...
Daiichi’s Japan Filing The First For Denosumab In RA
Daiichi Sankyo has filed for the approval in Japan of denosumab for rheumatoid arthritis, marking the first such filing for the Amgen-originated antibody in this setting.
'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public
A tense advisory committee meeting, where many of the panelists admitted they lacked a complete understanding about biosimilars and patient advocates expressed anxiety over the products, could signal difficulties with adoption and success in the marketplace.
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.